Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA, Glucose Monitoring Feb 02 | 2021Dexcom Super Bowl DTC; Pfizer Q4 and FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring Feb 01 | 2021CGM: SENS/Ascensia Reinitiate EU Eversense XL Commercial Activities; Nemaura Appoints Jay Warner as Head of US Commercial OperationsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, SGLT2i Jan 29 | 2021Lilly Advances 5 New CV/Met Assets to Ph1; Lilly Q4 and FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jan 28 | 2021Lilly and Life for a Child Expand Partnership; ViaCyte Appoints Michael Yang as CEOPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 27 | 2021Abbott Q4 ’20 Earnings Update and US DTC; Apple and Samsung Watch CGM?; Dario Acquires Upright TechnologiesPurchase Blast
$599
Posted in: Other, SGLT2i Jan 26 | 2021New Novartis CV Regulatory Comments; Novartis and J&J Q4 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Glucagon, SGLT2i Jan 25 | 2021Adocia Reports Positive BC Lispro Data with Tonghua Dongbao Insulin; January 25-29 CHMP AgendaPurchase Blast
$599
Posted in: Basal Insulin Jan 22 | 2021Biocon CY Q4 '20 (FY Q3 '21) Earnings Update; Biocon Biologics CEO ResignsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring Jan 21 | 2021Oramed Randomizes First Patients in Ph3 Oral Insulin Trial; Dario Hires New Employer Sales LeadPurchase Blast
$599
Posted in: Other Jan 20 | 2021Verquvo (Vericiguat) Approved by FDA; Label Analysis, Entresto and CYTK ImplicationsPurchase Blast
$599
Posted in: GLP-1RA, Other Jan 20 | 2021High-Dose Ozempic Filed with FDA; Andy Ajello Joins ViforPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Jan 19 | 2021Metacrine NASH Fast Track Designation; Senseonics Receives Positive Coverage Decision for EmblemHealth; Insulet Launches Omnipod DASH in CanadaPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Jan 14 | 2021JPM 2021 Day 4: Lexicon Poised for a Strong Comeback; Lexicon, Viatris, and Intercept @ JPM; Poxel/Metavant Partnership TerminatedPurchase Blast$599
Posted in: GLP-1RA, Other Jan 13 | 2021JPM 2021 Day 3: Bayer, Esperion, Precision Bio, Hikma, Vifor; High-dose Oral Sema PIONEER PLUS Trial Posted on CT.gov; Dario Announces Two New Additions to Scientific Advisory BoardPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Jan 12 | 2021JPM 2021 Day 2: LLY, NVO, ABT, PODD, AMRN, and IONS; Bayer’s Finerenone Receives Priority Review for DKDPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 11 | 2021CORRECTING AND REPLACING: JPM 2021 Day 1: DXCM, MDT, TDOC, NVS; FDA Accepts EMPEROR-Reduced sNDA Without Priority Review; Adocia to Develop Beta Cell Therapy for T1DM TreatmentPurchase Blast
$599
Posted in: Glucose Monitoring, SGLT2i Jan 08 | 2021Lifescan/Sanvita Complete CGM Pilot Study; Lupin's Generic Synjardy XR Receives Tentative FDA ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Jan 07 | 2021Tidepool Completes FDA Submission of Tidepool Loop; Diabeloop Partners with SFC Fluidics for AID SolutionPurchase Blast
$599
Posted in: SGLT2i Jan 06 | 2021Farxiga DAPA-CKD Receives Priority Review from FDAPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
